14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,8,10,12,14-octaen-8-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,8,10,12,14-octaen-8-ol
• 化学式: C₁₄H₈N₂O
• 分子量: 220.23
• InChiKey: KRIUNPBAQZGFQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] METHODS AND COMPOSITIONS FOR TDP-43 PROTEINOPATHIES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR DES PROTÉINOPATHIES TDP-43
  申请人：IPIERIAN INC

  公开号：WO2013169793A2

  公开（公告）日：2013-11-14

  Provided herein are methods for treating a subject suffering from a TDP-43 proteinopathy, e.g., sporadic ALS or FTD by administering to the subject a composition comprising a therapeutically effective amount of a JNK inhibitor, a MAPK inhibitor, a proteasome inhibitor, a Topoisomerase I inhibitor, a Topoisomerase II inhibitor, a HSP-90 inhibitor, a 5-HT antagonist, a CDK inhibitor, or a transcription inhibitor. The provided methods can also be used to reduce TDP-43 aggregation in human neural progenitors or neurons in neural progenitors or neurons that exhibit TDP-43 aggregates. In addition, methods are provided to identify agents that modulate (decrease or increase) TDP-43 aggregation in human neural progenitors or neurons that exhibit TDP-43 aggregates. Also provided are human induced pluripotent stem cell (hiPSC) lines generated from sporadic ALS patients, where the hiPSC lines may be differentiated into neural progenitors or neurons (e.g., motor progenitors and motor neurons) that exhibit a TDP-43 aggregate. Further provided are isolated populations of cells containing neural progenitors or neurons derived from the aforementioned hiPSC lines.